| Previous Close | 84.66 |
| Open | 84.66 |
| Bid | 84.45 x 400 |
| Ask | 85.45 x 200 |
| Day's Range | 84.51 - 85.53 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 3,951,914 |
| Avg. Volume | 3,559,839 |
| Market Cap | 89.14B |
| Beta | 0.17 |
| PE Ratio (TTM) | 40.98 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.46%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Investor's Business Daily•13 minutes ago
Nasdaq Futures Fall On Google; 4 Stocks Near Buys With Earnings Due
Nasdaq futures fell Monday evening as Apple retreated following its Q2 earnings. Four stocks near buy points report earnings Tuesday morning, including GM and 3M.
- Investor's Business Daily•3 hours ago
Could This Small Biotech Break Out On A Tie-Up With Eli Lilly?
Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.
- Reuters•5 hours ago
FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
